Sublingual immunotherapy: Recent advances

Allergology International

Volumn 62, Issue 4, 2013, Pages 415-423

  Compalati, Enrico ^a   Braido, Fulvio ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Allergy; Desensitization; Recent advances; SLIT; Sublingual allergen immunotherapy

Indexed keywords

ALLERGEN; BUDESONIDE; HYMENOPTERA VENOM; LATEX; VENOM;

ALLERGENICITY; ALLERGIC DISEASE; ASTHMA; ATOPIC DERMATITIS; DENDRITIC CELL; DERMATOPHAGOIDES; DESENSITIZATION; DNA MODIFICATION; DRUG SAFETY; FOOD ALLERGY; HUMAN; IMMUNE RESPONSE; ORAL IMMUNOTHERAPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT ALLERGY; REVIEW; SENSITIZATION; SUBLINGUAL IMMUNOTHERAPY;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALLERGENS; ANTIGEN PRESENTATION; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; PATIENT COMPLIANCE; RECOMBINANT PROTEINS; RESPIRATORY HYPERSENSITIVITY; SUBLINGUAL IMMUNOTHERAPY;

EID: 84890073104     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.13-RAI-0627     Document Type: Review

References (99)

1. Bernstein D, Wanner B, Borish L et al. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004;113:1129-36.
2. Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists' experiences and recommendations for prevention. J Allergy Clin Immunol 2004;113:1117-21.
3. Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986;16:483-91.
4. Bousquet J, Lockey R, Malling HJ. WHO Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998;53(Suppl S44):1-42.
5. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; WHO. Allergic rhinitiss and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl 5):S147-334.
6. Canonica GW, Bousquet J, Casale T et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009;64(Suppl 91):1-59.
7. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010;CD002893.
8. Calamita Z, Saconato H, Pela AB, Atallah NA. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials. Allergy 2006;61:1162-72.
9. Penagos M, Compalati E, Tarantini F et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in children: meta analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2006;97:141-8.
10. Penagos M, Passalacqua G, Compalati E. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133:599-609.
11. Nieto A, Mazon A, Pamies R, Bruno M, Navarro M, Montanes A. Sublingual immunotherapy for allergic respiratory diseases: An evaluation of meta-analyses. J Allergy Clin Immunol 2009;124:157-61.
12. Compalati E, Penagos M, Tarantini F. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol 2009;102:22-8.
13. ClinicalTrials. gov ldentifier: NCT00674700. A Randomized, DBPC, Multi-national Phase II_III Study of the Safety and Efficacy of Two Doses of Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Adult Patients Suffering From HDM Aller gic Rhinitis. Available at: http:__clinicaltrials.gov_show_N CT00674700. Accessed August 3, 2013.
14. Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol 2013;131: 1361-6.
15. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. Allergy Clin Immunol 2012;130:1097-107.
16. Cox L, Compalati E, Kundig T, Larche M. New directions in immunotherapy. Curr Allergy Asthma Rep 2013;13:178-95.
17. Lin SY, Erekosima N, Kim JM et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013;309:1278-88.
18. Kim JM, Lin SY, Suarez-Cuervo C et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics 2013;131:1155-67.
19. Passalacqua G, Baena-Cagnani CE, Bousquet J et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 2013;132:93-8.
20. Mosbech H. Tolerability and efficacy of house dust mite AIT. Allergy 2011;66 (Suppl 95):55-6.
21. ClinicalTrials. gov Identifier: NCT01433523. Efficacy of ALK House Dust Mite Allergy Immunotherapy Tablet in Subjects With House Dust Mite Induced Asthma. The MITRA Trial. Available at: http:__clinicaltrials.gov_show_NC T01433523. Accessed August 3, 2013.
22. Marogna M, Braidi C, Bruno ME et al. The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: A real-life randomised trial. Allergol Immunopathol (Madr) 2013;41: 216-24.
23. Passalacqua G, Compalati E, Canonica GW. Sublingual immunotherapy: other indications. Immunol Allergy Clin North Am 2011;31:279-87.
24. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol 2007;7:542-6.
25. Bussmann C, Böckenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006;118:1292-8.
26. Pajno GB, Caminiti L, Vita D et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007;120:164-70.
27. Qin YE, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. Int J Dermatol 2013. DOI: 10.1111_ijd.12302.
28. ClinicalTrials. gov Identifier: NCT01471119. Sublingual Immunotherapy in Patients With Atopic Dermatitis. Available at: http:__clinicaltrials.gov_show_NCT01471119. Accessed August 3, 2013.
29. Holt PG, Sly PD, Sampson HA et al. Prophylactic use of sublingual allergen immunotherapy in high-risk children: A pilot study. J Allergy Clin Immunol 2013;132:991-3.
30. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997;99 (Pt 1):744-51.
31. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992;90:256-62.
32. Enrique E, Pineda F, Malek T et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, doubleblind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 2005;116:1073-9.
33. Fernández-Rivas M, Garrido Fernández S, Nadal JA et al. Randomized double-blind, placebocontrolled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 2009;64:876-83.
34. Kim EH, Bird JA, Kulis M et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 2011;127:640-6.
35. Kulis M, Saba K, Kim EH et al. Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy. J Allergy Clin Immunol 2012;129:1159-62.
36. Fleischer DM, Burks AW, Vickery BP et al. Sublingual immunotherapy for peanut allergy: a randomized, doubleblind, placebo-controlled multicenter trial. J Allergy Clin Immunol 2013;131:119-27.
37. Moran TP, Vickery BP, Burks AW. Oral and sublingual immunotherapy for food allergy: current progress and future directions. Curr Opin Immunol 2013. DOI: 10.1016_j. coi.2013.07.011.
38. Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol 2012; 129:448-55.
39. Chin SJ, Vickery BP, Kulis MD et al. Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. J Allergy Clin Immunol 2013;132: 476-8.
40. Mauro M, Russello M, Incorvaia C et al. Birch-apple syndrome treated with birch pollen immunotherapy. Int Arch Allergy Immunol 2011;156:416-22.
41. Nucera E, Aruanno A, Rizzi A et al. Profilin desensitization in two patients with plant-derived food allergy. Int J Immunopathol Pharmacol 2012;25:531-5.
42. Cortellini G, Spadolini I, Santucci A et al. Improvement of shrimp allergy after sublingual immunotherapy for house dust mites: a case report. Eur Ann Allergy Clin Immunol 2011;43:162-4.
43. Nettis E, Delle Donne P, Di Leo E et al. Latex immunotherapy: state of the art. Ann Allergy Asthma Immunol 2012;109:160-5.
44. Patriarca G, Nucera E, Roncallo C et al. Sublingual desensitization in patients with wasp venom allergy: preliminary results. Int J Immunopathol Pharmacol 2008;21:669-77.
45. Severino MG, Cortellini G, Bonadonna P et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 2008;122:44-8.
46. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108(Suppl):S147-334.
47. Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851-7.
48. Marogna M, Tomassetti D, Bernasconi A et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008;101:206-11.
49. Didier A, Worm M, Horak F et al. Sustained 3-year efficacy of pre-and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2001;128:559-66.
50. Durham SR, Emminger W, Kapp A et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010;125:131-8.
51. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010;126:969-75.
52. Di Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33:206-10.
53. Tahamiler R, Saritzali G, Canakcioglu S. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope 2007;117:965-9.
54. Durham SR, Emminger W, Kapp A et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129:717-25.
55. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011;11:586-93.
56. Meadows A, Kaambwa B, Novielli N et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess 2013; 17:vi, xi-xiv, 1-322.
57. Brozek JL, Bousquet J, Baena-Cagnani CE et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76.
58. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQstandardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006;61:181-4.
59. Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011;127:30-8.
60. Calderón MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67:302-11.
61. Vovolis V, Kalogiros L, Mitsias D, Sifnaios E. Severe repeated anaphylactic reactions to sublingual immunotherapy. Allergol Immunopathol (Madr) 2013;41:279-81.
62. Cromwell O, Häfner D, Nandy A. Recombinant allergens for specific immunotherapy. J Allergy Clin Immunol 2011; 127:865-72.
63. Winther L, Poulsen LK, Robin B, Melac M, Malling H. Safety and tolerability of recombinant Bet v. 1 (rBet v 1) tablets in sublingual immunotherapy (SLIT) [abstract]. J Allergy Clin Immunol 2009;123(Suppl):S215.
64. Himly M, Carnés J, Fernández-Caldas E, Briza P, Ferreira F. Characterization of allergoids. Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess 2009;96:61-9; discussion 69-70.
65. Moingeon P. Sublingual immunotherapy: from biological extracts to recombinant allergens. Allergy 2006;61(Suppl 81):15-9.
66. Allam JP, Novak N, Fuchs C et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive Fc-epsilon-RI expression. J Allergy Clin Immunol 2003;112:141-8.
67. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006;61:151-65.
68. Mistrello G, Roncarolo D, Gentili M, Zanoni D, Falagiani P. Modified par j I allergen from P judaica pollen and its rate of absorption in rats. Immunol Lett 1994;40:31-6.
69. Mistrello G, Brenna O, Roncarolo D, Zanoni D, Gentili M, Falagiani P. Monomeric chemically modified allergens: immunologic and physicochemical characterization. Allergy 1996;51:8-15.
70. Lombardi C, Gargioni S, Melchiorre A et al. Safety of sublingual immunotherapy in adults: a post marketing surveillance study. Allergy 2001;56:989-92.
71. Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of sublingual immunotherapy in very young children. Allergy 2005;60:133.
72. Agostinis F, Foglia C, Bruno ME, Falagiani P. Efficacy, safety and tolerability of sublingual monomeric allergoid in tablets given without up-dosing to pediatric patients with allergic rhinitis and_or asthma due to grass pollen. Eur Ann Allergy Clin Immunol 2009;41:177-80.
73. Allam JP, Peng WM, Appel T et al. Toll-likereceptor4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008;121:368-74. e1.
74. Moingeon P, Lombardi V, Saint-Lu N, Tourdot S, Bodo V, Mascarell L. Adjuvants and vector systems for allergy vaccines. Immunol Allergy Clin North Am 2011;31:407-19.
75. Smits HH, Engering A, van der Kleij D et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing non integrin. J Allergy Clin Immunol 2005;115: 1260-7.
76. Allam JP, Novak N, Fuchs C et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive Fcepsilon-RI expression. J Allergy Clin Immunol 2003;112:141-8.
77. Pizza M, Giuliani MM, Fontana MR et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001;19:2534-41.
78. Uddowla S, Freytag LC, Clements JD. Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens. Vaccine 2007;25:7984-93.
79. Saint-Lu N, Tourdot S, Razafindratsita A et al. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 2009;64:1003-13.
80. Novak N, Bieber T, Allam JP. Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy 2011;66:733-9.
81. Pfaar O, Barth C, Jaschke C, Hörmann K, Klimek L. Sublingual allergen-specificimmunotherapy adjuvanted with monophosphoryl lipid A: a phase I_IIa study. Int Arch Allergy Immunol 2011;154:336-44.
82. Mistrello G, Brenna O, Roncarolo D, Zanoni D, Gentili M, Falagiani P. Monomeric chemically modified allergens: immunologic and physicochemical characterization. Allergy 1996;51:8-15.
83. Passalacqua G, Albano M, Fregonese L et al. Randomised controlled trial of local allergoids immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351:629-32.
84. Cosmi L, Santarlasci V, Angeli R et al. Sublingual immu notherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma and interleukin-10-production. Clin Exp Allergy 2006;36:261-72.
85. Bagnasco M, Mariani G, Passalacqua G et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by non injectable routes in healthy human beings. J Allergy Clin Immunol 1997;100: 122-9.
86. Durham SR. Sublingual immunotherapy: what have we learnt from the 'big trials'? Curr Opin Allergy Clin Immunol 2008;8:577-84.
87. Shamji MH, Ljørring C, Würtzen PA. Predictive biomarkers of clinical efficacy of allergen-specific immunotherapy: how to proceed. Immunotherapy 2013;5:203-6.
88. Shamji MH, Ljorring C, Francis JN et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012;67:217-26.
89. Zimmer A, Bouley J, Le Mignon M et al. A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy. J Allergy Clin Immunol 2012;129:1020-30.
90. Stelmach I, Kaluziska-Parzyszek I, Jerzynska J, Stelmach P, Stelmach W, Majak P. Comparative effect of precoseasonal and continuous grass sublingual immunotherapy in children. Allergy 2012;67:312-20.
91. Quercia O, Bruno ME, Compalati E, Falagiani P, Mistrello G, Stefanini GF. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens. Eur Ann Allergy Clin Immunol 2011;43:176-83.
92. Lombardi C, Incorvaia C, Braga M, Senna G, Canonica GW, Passalacqua G. Administration regimens for sublingual immunotherapy to pollen allergens: what do we know? Allergy 2009;64:849-54.
93. Pajno GB, Caminiti L, Crisafulli G et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediat Allergy Immunol 2011;22:803-7.
94. Larenas-Linnemann D, Esch R, Plunkett G et al. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. Ann Allergy Asthma Immunol 2011;107:448-58.
95. Chapman MD, Ferreira F, Villalba M et al. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol 2008;122:882-9.
96. Baron-Bodo V, Batard T, Nguyen H et al. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Clin Exp Allergy 2012; 42:1510-8.
97. Marcucci F, Sensi L, Incorvaia C, Dell'Albani I, Di Cara G, Frati F. Specific IgE response to different grass pollen allergen components in children undergoing sublingual immunotherapy. Clin Mol Allergy 2012;10:7.
98. Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol 2013;132: 353-60.
99. Savi E, Peveri S, Senna G, Passalacqua G. Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. Allergy 2013;68:1193-5.